Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02253316 · ClinicalTrials.gov registry record · Phase 2

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Washington University School of Medicine.

Active
Registry status
Phase 2
Development phase
236
Enrollment target
10
Study locations

NCT02253316 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 236 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (57% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02253316, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
236 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen consisting of ixazomib, lenalidomide (also called Revlimid), and dexamethasone. After 4 cycles of IRD, the participants will be randomized to receive maintenance therapy either with ixazomib or lenalidomide.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • BIOLOGICAL Ixazomib

Study Locations (10)

California

  • City of Hope - Duarte
  • University of California, San Francisco - San Francisco

Colorado

  • Colorado Blood Cancer Institute - Denver

Georgia

  • Emory University - Winship Cancer Institute - Atlanta

Michigan

  • Karmanos Cancer Institute - Detroit

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 236 participants
Start Date 2015-01-20
Est. Completion 2026-08-31
Phase Phase 2

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02253316

The ClinicalTrials.gov registry entry for NCT02253316 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (57% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT02253316 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT02253316 about?

NCT02253316 is a clinical study titled "Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma". The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen consisting of ixazomib...

What is the current status of trial NCT02253316?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2015-01-20. Estimated completion is 2026-08-31.

What conditions does trial NCT02253316 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT02253316?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Ixazomib (BIOLOGICAL).

Who is sponsoring clinical trial NCT02253316?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02253316 being conducted?

This trial has 10 study locations across California, Colorado, Georgia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.